BioCentury
ARTICLE | Clinical News

TTI-621: Ph I started

February 1, 2017 9:45 PM UTC

Trillium began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate single and multiple doses of 3 dose levels of intratumoral TTI-621 in about 54 patients....

BCIQ Company Profiles

Trillium Therapeutics Inc.

BCIQ Target Profiles

CD47